SCHEMBL30008274

SCHEMBL30008274

O=P(O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2ncc3c(NOCc4ccccc4)nc(Cl)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.80

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NT5E P21589 17/20 0.80
P2RY6 Q15077 3/20 0.61
P2RY14 Q15391 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27195252 1.00 NT5E (0.80) NT5EP2RY6P2RY14
SCHEMBL19100633 0.89 NT5E (1.00) NT5E
SCHEMBL27206860 0.86 NT5E (0.78) NT5E
SCHEMBL27195143 0.86 NT5E (0.78) NT5E
SCHEMBL30008031 0.86 NT5E (0.78) NT5E
SCHEMBL19100837 0.84 NT5E (0.77) NT5E
SCHEMBL30008194 0.84 NT5E (0.56) NT5E
SCHEMBL30008606 0.84 NT5E (0.74) NT5E
SCHEMBL27195105 0.84 NT5E (0.74) NT5E
SCHEMBL19100518 0.84 NT5E (1.00) NT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368204-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-11-07 US disclosed
EP-4353732-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2024-04-17 EP disclosed
WO-2022237747-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF 四川海思科制药有限公司 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368204-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF ENTPD5, ENTPD1, ENTPD2 NT5E 6/4885P2RY6 20/4885P2RY14 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.